Research and Clinical Trials

The Division of Hematology & Medical Oncology oversees a significant research program, in which we participate in development of novel treatments, translational research, cancer epidemiology and prevention, and health disparities in oncology. Each faculty member represents an area of cancer research, and each has built a team focusing on a specific cancer problem. Our clinical investigators are able to draw on the discoveries from the best new leads by industrial collaborators, and from colleagues from collaborating institutions. Researchers from our division enjoy support from the National Institutes of Health, non-profit cancer research foundations, and industry finds.

Our clinical trials:

  • HER2CLIMB-05: A Randomized, Double-Blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer
  • A Randomized, Double-blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With Nivolumab in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting
  • CO44194 A Phase II Multicenter, Randomized, Double-Blind study of R07247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in participants with Previously Untreated, PDL1 Positive, Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer
  • J3M-MC-JZQB: A Global Pivotal Study In Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing 1L treatment of Pembrolizumab and LY3537982 vs Pembrolizumab and Placebo in those with high PD-L1 expression (TPS ≥ 50%) and ChemoIO and LY3537892 vs ChemoIO and Placebo regardless of PDL1 TPS
  • An Interventional, Double Blind, Randomized, Multicenter Phase 3 Study of PF-07220060 Plus Fulvestrant Compared to Fulvestrant in Participants Over 18 years of Age with HR+HER2- Advanced or Metastatic Breast Cancer whose Disease Progressed After Prior CDK 4/6 Inhibitor Based Therapy
  • pionERA: A Phase 3, Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both Combined with a CDK4/6 Inhibitor, in Patients with ER+HER2- Advanced Breast Cancer with Resistance to Prior Adjuvant Endocrine Therapy
  • LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC.
  • CemiplimAb-rwlc Survivorship Epidemiology (CASE) Study.
  • BESPOKE Study of ctDNA Guided Immunotherapy (BESPOKE IO).
  • Clinical Utility of Circulating Tumor DNA (ctDNA) in Patients with Head and Neck Cancer.
  • PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib.
  • A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.
  • A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202).
  • BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer.
  • A multicenter, single-arm, open label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult aHUS patients who are naive to complement inhibitor therapy.
  • A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA.
  • A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
  • A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)
  • An open label, multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation.
  • A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation.
  • A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopan
  • A Phase 2 Study of Pembrolizumab (MK-3475) every 6 weeks (Q6W) in Participants with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
  • A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies
  • Clinical Utility of Circulating Tumor DNA (ctDNA) in Patients with Aggressive, B-Cell Lymphoma receiving Standard of Care Therapy.
  • Effect of Multi-kinase Inhibitors and Immune-checkpoint Inhibitors on Human Spermatogenesis.

Our collaborators: